Transformed Indolent B-cell Non-hodgkin Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2025-01-07
Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial of ibrutinib in patients with relapsed or refractory transformed indolent B-cell non-Hodgkin lymphoma; results have been poste…